System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Eric Guedj is an expert in Neurology at Hôpitaux universitaires de Marseille (France). As of September 2026, ScienceLeadR ranks Eric Guedj in the top 1% of experts worldwide for Coronavirus Infections, COVID-19 and Pneumonia. Eric Guedj has authored 395 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 2 of them ongoing. SLR score: 1,360 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Eric Guedj Hôpitaux universitaires de Marseille France
1 360 ScienceLeadR Reputation 1360

Unlock

Register Login
Network Map

Neurology

Subspecialties: Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Hôpital de la Timone

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 395

Citations

Citations: 10 694 1st author: 56 Last author: 109 Unique author: 4

Main journals

Eur J Nucl Med Mol Imaging 53
MED NUCL 30
Rev Neurol (Paris) 21
Neurology 15
Research Square (Research Square) 11

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
18F-Fluorodeoxyglucose PET, the Brain, and Other Organs: From the First Human Studies (1976) to 2026.
PMID 42481350 — positron-emission tomography, brain, fluorodeoxyglucose f18		PET Clin20260
Dopaminergic vulnerability in long COVID: striatal PET imaging at the brain-body interface.
PMID 42431744 — biomedical research, positron-emission tomography, brain, post-acute covid-19 syndrome		EBioMedicine20260
How Fluorine-18-labeled Fluorodeoxyglucose PET Changed Clinical Practice in Central Nervous System Disorders.
PMID 42409692 — central nervous system diseases, positron-emission tomography, biomarkers, central nervous system, fluorodeoxyglucose f18, nervous system, nervous system diseases		PET Clin20260
Future Directions for [18F]FDG PET in Central Nervous System Diseases.
PMID 42409693 — central nervous system diseases, positron-emission tomography, brain, central nervous system, fluorodeoxyglucose f18, nervous system, nervous system diseases		PET Clin20260
Five Decades of [18F]Fluorodeoxyglucose-PET in Neuropsychiatric Disorders: From Brain Metabolism to Precision Functional Imaging.
PMID 42362412 — positron-emission tomography, brain, fluorodeoxyglucose f18		PET Clin20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

N/A 5
Early Phase 1 1
Phase 3 1
Phase 4 1

By status:

Completed 3
Unknown 3
Recruiting 2

By type:

Interventional 8

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 0
multicentricup10 0

Main Topics

Cohort/Consortium Investigators 7

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Creation of a Database of Healthy Subjects With 18FDG PET Brain Imaging as Part of the MOBILE Project (Multimodal Whole Brain Imaging in Epilepsy)
NCT06976788 — epilepsy, tomography, positron-emission tomography, brain, healthy volunteers, fluorodeoxyglucose f18, research		N/ARecruiting2024
Evaluation of Diagnostic Performances of 18F FDOPA PET KInetics
NCT05512403 — injections, fasting, glioma, premedication, positron emission tomography computed tomography, biomarkers, carbidopa, wounds and injuries		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS